Eradication of the development of HCC in patients with chronic hepatitis C and liver cirrhosis

DOI Web Site 13 References
  • MORIYAMA Mitsuhiko
    Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine

Bibliographic Information

Other Title
  • 慢性肝炎から肝細胞がんの撲滅に向けて
  • 第50回総会 会長講演 慢性肝炎から肝細胞がんの撲滅に向けて
  • ダイ50カイ ソウカイ カイチョウ コウエン マンセイ カンエン カラ カン サイボウ ガン ノ ボクメツ ニ ムケテ

Search this article

Abstract

The Japanese Society of Gastroenterological Cancer Screening is celebrating its 50th anniversary this year. In this paper, we describe the prediction and prevention treatment of hepatocellular carcinoma (HCC) in present times. First, let me describe the patients with chronic hepatitis C who are included in the high-risk group for the development of HCC. When we analyzed the high-risk group for HCC development in patients with chronic hepatitis C who were treated with interferon alpha agents, it included elderly, male patients with a platelet count of less than 150,000 and an ALT value of less than 80IU/L. <BR>Furthermore, I shall describe the prevention treatment for HCC development. IFN treatment may be considered as the primary or secondary prevention treatment of HCC resulting from chronic hepatitis C. Our facilities monitored the long-term outcome in patients who underwent IFN therapy from 1992 to 2011, prospectively. We examined the long-term outcome in these IFN treated patients by analyzing the cumulative incidence of HCC development in them. As a result, the cumulative incidence of HCC development in patients with IFN therapy is significantly low compared to that in IFN untreated patients. When I compared the incidence of HCC in patients with ALT levels between less than 80IU/L and greater than 80IU/L under IFN treatment after the IFN administration periods, the cumulative incidence of HCC development in patients with ALT levels below 80IU/L was significantly lower than that in patients with ALT levels over 80IU/L. Even in patients at stages F3 or F4, IFN administration is suggested to suppress the development of HCC in chronic hepatitis C patients compared to IFN untreated patients. In conclusion, IFN administration improves the long-term outcome in patients with chronic hepatitis C by suppressing the development of HCC resulting from chronic hepatitis C.

Journal

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top